MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...

After an IPO this year, Metsera is making its best effort to catch up to obesity drug giants Eli Lilly and Novo Nordisk.

Metsera ,” said Whit Bernard, CEO. “We advanced MET-097i, our monthly, fully-biased GLP-1 RA injectable, from f ...

Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

So far this year, 11 U.S. venture-backed private companies have gone public or agreed to be acquired at valuations of $1 billion or more, per Crunchbase data. That’s more than double the number from ...

three insiders acquired a total of $94.22 million in Metsera shares at $18 per share during the company’s initial public offering. The company raised $257 million during its IPO, pricing shares ...

The newly listed clinical-stage biotechnology company, Metsera Inc. MTSR rose 15.01% on Monday as the broader markets declined. What Happened: While the company reported insider trades over the ...

With the completion of our recent IPO, we have substantial capital to ... as we rapidly advance Metsera’s portfolio of ultra-long acting, scalable and combinable injectable and oral candidates.” ...

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other stocks with at least $10 million in insider spending recently. Since Donald Trump took office ...

In February, Metsera completed an IPO, raising approximately $316.2 million in aggregate gross proceeds from the offering before deducting underwriting discounts, commissions and other offering ...